Insmed | INSM - Operating Profit


Insmed reported $-249.71M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Cytokinetics USD -178.37M 11.61M Dec/2025
DBV Technologies USD -34.28M 6.83M Sep/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Novartis USD 4.58B 879M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025